Compare Organon & Co. Common Stock (OGN) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Weibo Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Weibo Corp trades at $6.43 (market cap $1.61B). The key difference: Organon & Co. Common Stock is far larger — about 2.2× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.3%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Weibo Corp for 103 Days on average.
| OGN | WB | |
|---|---|---|
Market Cap | $3.62B | $1.61B |
Volume | 2,892,999 | 585,008 |
Sector | Health | Media |
52-Week High | $13.81 | $11.52 |
52-Week Low | $5.70 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $11.04B | $841.53M |
Dividend Yield | 0.58% | 9.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Weibo (WB) trades at $6.51, down 0.53% with bearish technical signals despite attractive valuation metrics including a P/E of 5.42 and P/B of 0.4. The company reported Q2 2026 EPS of $0.38, beating expectations, but faces declining user metrics and advertising revenue challenges. Cash flow trends show volatility with a significant net outflow in 2024 followed by recovery in 2025.
WB presents as a deep-value opportunity with strong profitability margins but faces growth headwinds from user engagement declines and competitive pressures. Analyst sentiment is mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
